Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial
Drenthen LCA, de Baaij JHF, Rodwell L, van Herwaarden AE, Tack CJ, de Galan BE
Diabetologia · 21 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Diabetes Fonds
- Universidad u hospital
- Radboud Universitair Medisch Centrum
- Organización sin fines de lucro
- European Association for the Study of Diabetes
- Subvenciones
- Diabetes Fonds (2017.81.014)
Según 3 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2023-11-03 · Diabetologia · vol. 67 · número 1 · págs. 52–61
- Editorial
- Springer Science+Business Media
- Citado
- 21 citas · más que el 90% de estudios similares · 2.6× el promedio de su campo
- Referencias
- 47 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY
- Áreas de investigación
- Magnesium in Health and Disease · Parathyroid Disorders and Treatments · Potassium and Related Disorders
- Palabras clave
- Medicine, Type 2 diabetes, Internal medicine, Insulin, Placebo, Diabetes mellitus, Crossover study, Endocrinology, Population, Insulin resistance, Gastroenterology, Randomized controlled trial
- MeSH
- humans, diabetes mellitus, type 2, insulin resistance, magnesium, insulin, blood glucose, lipids, hypoglycemic agents, blood glucose self-monitoring, cross-over studies, double-blind method, dietary supplements, adolescent, aged, middle aged, female, male
6 autores
- Linda C. A. Drenthen🇳🇱 · autor de correspondenciaRadboud University Nijmegen; Radboud University Medical Center; Radboud Institute for Molecular Life Sciences
- Jeroen H. F. de Baaij🇳🇱Radboud University Nijmegen; Radboud University Medical Center
- Laura Rodwell🇳🇱Radboud University Nijmegen; Radboud University Medical Center
- Antonius Eduard van Herwaarden🇳🇱Radboud University Nijmegen; Radboud University Medical Center
- Cees J. Tack🇳🇱Radboud University Nijmegen; Radboud University Medical Center
- Bastiaan E. de Galan🇳🇱Radboud University Nijmegen; Radboud University Medical Center; Maastricht University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Aims/hypothesis
Hypomagnesaemia has been associated with insulin resistance and an increased risk of type 2 diabetes. Whether magnesium supplementation improves insulin sensitivity in people with type 2 diabetes and a low serum magnesium level is unknown.
Methods
Using a randomised, double-blind (both participants and investigators were blinded to the participants' treatment sequences), placebo-controlled, crossover study design, we compared the effect of oral magnesium supplementation (15 mmol/day) for 6 weeks with that of matched placebo in individuals with insulin-treated type 2 diabetes (age ≥18 years, BMI 18-40 kg/m2, HbA1c <100 mmol/mol [11.3%], serum magnesium ≤0.79 mmol/l). Participants were recruited from the outpatient clinic and through advertisements. Randomisation to a treatment sequence order was done using a randomisation list. We used block randomisation and the two possible treatment sequences were evenly distributed among the trial population. The primary outcome was the mean glucose infusion rate during the final 30 min of a hyperinsulinaemic-euglycaemic clamp (i.e. M value). Secondary outcomes included variables of glucose control, insulin need, BP, lipid profile and hypomagnesaemia-related symptoms during follow-up.
Results
We recruited 14 participants (50% women, 100% White, mean ± SD age 67±6 years, BMI 31±5 kg/m2, HbA1c 58±9 mmol/mol [7.4±0.9%]) with insulin-treated type 2 diabetes. Magnesium supplementation increased both mean ± SEM serum magnesium level (0.75±0.02 vs 0.70±0.02 mmol/l, p=0.016) and urinary magnesium excretion (magnesium/creatinine ratio, 0.23±0.02 vs 0.15±0.02, p=0.005), as compared with placebo. The M value of the glucose clamp did not differ between the magnesium and placebo study arms (4.6±0.5 vs 4.4±0.6 mg kg-1 min-1, p=0.108). During the 6 weeks of treatment, continuous glucose monitoring outcomes, HbA1c, insulin dose, lipid profile and BP also did not differ, except for a lower HDL-cholesterol concentration after magnesium compared with placebo (1.14±0.08 vs 1.20±0.09 mmol/l, p=0.026). Symptoms potentially related to hypomagnesaemia were similar for both treatment arms.
Conclusions/interpretation
Despite an albeit modest increase in serum magnesium concentration, oral magnesium supplementation does not improve insulin sensitivity in people with insulin-treated type 2 diabetes and low magnesium levels.
Trial registration
EudraCT number 2021-001243-27.
Funding
This study was supported by a grant from the Dutch Diabetes Research Foundation (2017-81-014).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.